Ayse Tugce Sahin

Ayse Tugce Sahin

Auto-generated profile, based on publicly available information

Ayse Tugce Sahin

Helmholtz Pioneer Campus, Helmholtz Zentrum München, Neuherberg, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
DRDoris Roth
Doris Roth
AŞAyşe Tuğçe Şahin
Ayşe Tuğçe Şahin
FLFeng Ling
Feng Ling
NTNiels Tepho
Niels Tepho
CSChristiana N. Senger
Christiana N. Senger
ARAmy Leanne Ryan
Amy Leanne Ryan
Mucociliary clearance is a vital defense mechanism of the human airways, protecting against harmful particles and infections. When this process fails, it contributes to respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma. While advances in single-cell transcriptomics have revealed the complexity of airway composition, much of what we know about how airway structure impacts clearance relies on animal studies. This limits our ability to create accurate human-based models of airway diseases. Here we show that the airways in female rats and in humans exhibit species-specific differences in the distribution of ciliated and secretory cells as well as in ciliary beat, resulting in significantly higher clearance effectiveness in humans. We further reveal that standard lab-grown cultures exhibit lower clearance effectiveness compared to human airways, and we identify the underlying structural differences. By combining diverse experiments and physics-based modeling, we establish universal benchmarks to assess human airway function, interpret preclinical models, and better understand disease-specific impairments in mucociliary clearance.

25 October 2022 in Proteomics – Clinical Applications
Verified
Journal Article
Closed access
ASAyse Tugce Sahin
Ayse Tugce Sahin
AYAli Yurtseven
Ali Yurtseven
SDSina Dadmand
Sina Dadmand
GOGulin Ozcan
Gulin Ozcan
BABusra A. Akarlar
Busra A. Akarlar
NONurhan Ozlu
Nurhan Ozlu

11 May 2021 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
ASAydanur Senturk
Aydanur Senturk
ASAyse T. Sahin
Ayse T. Sahin
AAAyse Armutlu
Ayse Armutlu
MKMurat C. Kiremit
Murat C. Kiremit
OAOmer Acar
Omer Acar
NONurhan Ozlu
Nurhan Ozlu
Clear cell renal cell carcinoma (ccRCC) is the third most common and most malignant urological cancer, with a 5-year survival rate of 10% for patients with advanced tumors. Here, we identified 10,160 unique proteins by in-depth quantitative proteomics, of which 955 proteins were significantly regulated between tumor and normal adjacent tissues. We verified four putatively secreted biomarker candidates, namely, PLOD2, FERMT3, SPARC, and SIRPα, as highly expressed proteins that are not affected by intratumor and intertumor heterogeneity. Moreover, SPARC displayed a significant increase in urine samples of patients with ccRCC, making it a promising marker for the detection of the disease in body fluids. Furthermore, based on molecular expression profiles, we propose a biomarker panel for the robust classification of ccRCC tumors into two main clusters, which significantly differed in patient outcome with an almost three times higher risk of death for cluster 1 tumors compared with cluster 2 tumors. Moreover, among the most significant clustering proteins, 13 were targets of repurposed inhibitory FDA-approved drugs. Our rigorous proteomics approach identified promising diagnostic and tumor-discriminative biomarker candidates which can serve as therapeutic targets for the treatment of ccRCC. Implications: Our in-depth quantitative proteomics analysis of ccRCC tissues identifies the putatively secreted protein SPARC as a promising urine biomarker and reveals two molecular tumor phenotypes.

21 September 2022 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
ASAydanur Senturk
Aydanur Senturk
ASAyse T. Sahin
Ayse T. Sahin
AAAyse Armutlu
Ayse Armutlu
MKMurat Can Kiremit
Murat Can Kiremit
OAOmer Acar
Omer Acar
NONurhan Ozlu
Nurhan Ozlu
Clear cell Renal Cell Carcinoma (ccRCC) is among the 10 most common cancers in both men and women and causes more than 140,000 deaths worldwide every year. In order to elucidate the underlying molecular mechanisms orchestrated by phosphorylation modifications, we performed a comprehensive quantitative phosphoproteomics characterization of ccRCC tumor and normal adjacent tissues. Here, we identified 16,253 phosphopeptides, of which more than 9000 were singly quantified. Our in-depth analysis revealed 600 phosphopeptides to be significantly differentially regulated between tumor and normal tissues. Moreover, our data revealed that significantly up-regulated phosphoproteins are associated with protein synthesis and cytoskeletal re-organization which suggests proliferative and migratory behavior of renal tumors. This is supported by a mesenchymal profile of ccRCC phosphorylation events. Our rigorous characterization of the renal phosphoproteome also suggests that both epidermal growth factor receptor and vascular endothelial growth factor receptor are important mediators of phospho signaling in RCC pathogenesis. Furthermore, we determined the kinases p21-activated kinase 2, cyclin-dependent kinase 1 and c-Jun N-terminal kinase 1 to be master kinases that are responsible for phosphorylation of many substrates associated with cell proliferation, inflammation and migration. Moreover, high expression of p21-activated kinase 2 is associated with worse survival outcome of ccRCC patients. These master kinases are targetable by inhibitory drugs such as fostamatinib, minocycline, tamoxifen and bosutinib which can serve as novel therapeutic agents for ccRCC treatment.

14 January 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
FLFeng Ling
Feng Ling
AŞAyşe Tuǧçe Şahin
Ayşe Tuǧçe Şahin
BNBernardo Miller Naranjo
Bernardo Miller Naranjo
SAStefano Aime
Stefano Aime
DRDoris Roth
Doris Roth
JNJanna Nawroth
Janna Nawroth
One-Sentence Summary: We here develop and validate an easy to implement, high-throughput microrheology platform to reliably quantify viscoelasticity in as little as 3 µL mucus droplet samples or intact mucosal surfaces based on Differential Dynamic Microscopy (DDM) that we demonstrate in a variety of in vitro and clinical applications. Mucus plays an integral role in the barrier function of many epithelial tissues, including respiratory, gastrointestinal, and reproductive systems. Understanding how mucus flow behavior, i.e., rheology, changes during disease progression and in response to treatments is of great interest for better differential diagnostics, pinpointing patient-specific disease mechanisms and respective personalized treatments. However, both basic and translational research of mucus rheology is greatly hampered by the lack of scalable and user-friendly rheology assays for the small volumes of mucus typically provided by in vitro respiratory models or from clinical samples. We report a streamlined, high-throughput, semi-automated mucus rheology approach, easy to implement for a variety of preclinical and clinical questions. It leverages Differential Dynamic Microscopy (DDM) to reliably measure the frequency-dependent microrheology of minuscule (3–10 µL-sized) mucus samples as well as in situ mucosal surfaces using standard epifluorescence microscopy. Overcoming complex and time-consuming user interventions of previous rheology and particle tracking routines, we achieve microrheology at the time scale of mucus relaxation (1–20 s), greatly reducing assay time. We validated our platform successfully in mucus samples and in situ mucosal surfaces: first in state-of-the-art air-liquid-interface (ALI) human respiratory cultures, where we compare mucus rheology of airway disease models and different culture conditions; second, assessing clinical samples of human patient cervical samples. Overall, our results add to an increasingly appreciated non-invasive, easy to use, body fluid-based personalized toolbox, with unprecedented opportunities for precision medicine and large-scale monitoring to further unveil functional roles of mucus in human health and disease.

3 April 2023
Verified
Other
Open access
ASAydanur Senturk
Aydanur Senturk
ASAyse T. Sahin
Ayse T. Sahin
AAAyse Armutlu
Ayse Armutlu
MKMurat C. Kiremit
Murat C. Kiremit
OAOmer Acar
Omer Acar
NONurhan Ozlu
Nurhan Ozlu
Supplementary Data from Quantitative Proteomics Identifies Secreted Diagnostic Biomarkers as well as Tumor-Dependent Prognostic Targets for Clear Cell Renal Cell Carcinoma